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The last decade has seen major progress at all levels of
neuroscience, from genes and molecules up to integrated
systems-level models of brain function. In particular, there
have been advances in the understanding of cell-type-spe-
cific contributions to function, together with a clearer
account of how these contributions are coordinated from
moment to moment to organise behavior. A major current
endeavor is to leverage this knowledge to develop new
therapeutic approaches. In Parkinson’s disease, there are
a number of promising emerging treatments. Here, we will
highlight three ambitious novel therapeutic approaches
for this condition, each robustly drivenbyprimary neurosci-
ence. Pharmacogenetics genetically re-engineers neu-
rons to produce neurotrophins that are neuroprotective to
vulnerable dopaminergic cells or to directly replace dopa-
mine through enzyme transduction. Deep brain stimulation
(DBS) is undergoing a transformation, with adaptive DBS
controlled by neural signals resulting in better motor out-
comes and significant reductions in overall stimulation
that could reduce side effects. Finally, optogenetics pre-
sents the opportunity to achieve cell-type-specific control
with a high temporal specification on a large enough scale
to effectively repair network-level dysfunction.
Introduction
Dr James Parkinson, a London apothecary surgeon, defined
the symptomatology, inexorable progression and burden of
Parkinson’s disease (PD) in his brilliant treatise An Essay on
the Shaking Palsy in 1817 [1]. In this he expressed his opti-
mism ‘‘that some remedial process may ere long be discov-
ered, by which, at least, the progress of the disease may be
stopped’’. Almost two hundred years later we are yet to
vindicate his hopes with the discovery of a treatment that
ceases progression, but we are beginning to see exciting
new means by which the symptoms of this devastating dis-
ease may be better ameliorated.
Initially, PD was thought to be an acquired disorder but
twin studies have revealed that inheritability plays a particu-
larly strong role in patients who develop the condition below
the age of fifty [2]. Subsequent investigation has delineated a
number of single gene disorders which account for 5–10% of
patients, and some common variants that confer additional
risk to many others [3,4]. At the cellular level, idiopathic PD
is particularly, but not exclusively, characterised by severe
loss of dopaminergic neurons in the substantia nigra pars
compacta and the accumulation of intracellular, cytoplasmic
alpha-synuclein in the form of Lewy bodies [5,6]. Disease
progression is associated with the spread of Lewy-body pa-
thology rostrally up the brainstem to the mesocortex and
finally neocortex, with the development of associated clinical
signs [7]. Recent work raises the possibility that this spread
may reflect a prion-like process whereby alpha-synucleinNuffield Department of Clinical Neurosciences, John Radcliffe
Hospital, University of Oxford, OX3 9DU, UK.
*E-mail: peter.brown@ndcn.ox.ac.ukinduces pathological refolding in previously healthy proteins
with resultant Lewy-body aggregation [8,9]. The underlying
molecular pathology is complex, involving many different
molecular pathways, including protein folding and clear-
ance, mitochondrial function/oxidative stress and the ubiq-
uitin–proteasome system [10].
PD can manifest with diverse motor, cognitive, affective
and autonomic symptoms. Impairment of voluntary move-
ment may take the form of slowness (bradykinesia), stiffness
(rigidity), tremor and postural instability, leading to falls [11].
With the exception of postural instability these motoric
symptoms are the most readily treated. To this end, the
gold-standard therapy is dopaminergic replacement using
oral levodopa, a precursor of dopamine [12]. However, it is
increasingly acknowledged that the PD-associated dopami-
nergic denervation of the basal ganglia is not homogeneous,
and exogenous dopaminergic therapy with levodopa or
dopamine agonists can itself be associated with side effects,
like impulsivity, due to overstimulation in the ventral striatum
where dopaminergic innervation remains relatively intact
[13]. Moreover, PD is slowly progressive and, during the
course of the disease, possibly partly in response to pulsatile
oral dopaminergic therapy, paradoxical involuntary move-
ments, termed dyskinesias, and unpredictable fluctuations
in medication response develop in the majority of cases [14].
Such complications motivated the development of electri-
cal deep brain stimulation (DBS), which involves the implan-
tation of chronic electrodes into selected, focal basal ganglia
structures (Figure 1) and, after connection to an internalised
battery-powered stimulator, the delivery of continuous elec-
trical stimulation using brief pulses at a set frequency that is
most commonly above 100 Hz. Over 100,000 patients world-
wide have undergone DBS, in particular for PD and tremor,
with beneficial outcomes that are sustained and exceed
those achievable in comparable patients treated only with
oral medication [15–19]. Still DBS is by no means perfect,
as patients show only partial responses that are complicated
by side effects related to both surgery and, as will be dis-
cussed, continuous, regular stimulation. Indeed, it is remark-
able quite how effective it is, given that stimulation generally
consists of continuous high-frequency pulses, regardless of
aetiology or patient state.
The limitations of both current pharmacological and surgi-
cal therapies highlight the need to interact with the brain
with better spatial and temporal control. Here, our aim is
to critically review and discuss emerging therapies that could
deliver such improved spatiotemporal targeting. Three broad
approaches are being taken. Firstly, there are attempts to
restore physiologically appropriate spatiotemporal patterns
of brain activity through the replacement and protection of
dopaminergic neurons or the re-engineering of other cell
types toproducedopamineviapharmacogenetics.Secondly,
there are moves to improve on electrical DBS techniques so
that they impose more appropriate temporal patterning on
the nervous system, i.e. adaptive DBS. Finally, we discuss a
technique which brings together both spatial and temporal
targeting in animal models, namely optogenetics. These ad-
vances should improve therapeutic efficacy whilst reducing
side effects and could ultimately provide benefit across a
wide range of neuropsychiatric disorders.
Figure 1. Schematic of the classic model of motor loops between the
cortex and the basal ganglia.
Note the excitatory glutamatergic connections (red) and the inhibitory
GABA-ergic neurons (blue). Direct and indirect connections are high-
lighted with dissociated dopamine receptor associations. The hyper-
direct pathway between cortex and subthalamic nucleus (STN) is
also shown. DBS treatment for PD involves implantation of electrodes
into the STN, globus pallidus interna (GPi ) or thalamus depending on
the patient phenotype. D1 and D2 dopamine receptors are excited
and inhibited by dopamine released from the substantia nigra pars
compacta. GPe, globus pallidus externa. Adapted with permission
[102].
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One early approach to restore dopaminergic stimulation
with a physiologically appropriate spatiotemporal pattern
involved the replacement of dopaminergic neurons with em-
bryonic dopaminergic cells [20]. Although the overall results
of the clinical trials were negative, they did provide proof of
principle that cell transplantation can successfully re-inner-
vate the striatum and provide symptomatic relief in a minor-
ity of cases. However, this was at the cost of troublesome
dyskinesias (despite withdrawal of levodopa in some pa-
tients), believed to be due to anomalous serotoninergic
innervation of the striatum [21]. In view of these setbacks
and because of additional ethical and practical obstacles in
obtaining reliable and homogenous embryonic grafts, atten-
tion shifted to the use of stem cells which could potentially
provide unlimited standardised dopaminergic neurons for
implantation. This shows promise with both embryonic and
fibroblast-derived stem cells (neuroblasts) differentiating
into dopaminergic neurons, surviving transplantation into
rodent models and resulting in a degree of functional recov-
ery [22,23]. Dopaminergic neuronsmay even be directly con-
verted from fibroblasts. However, such research is still at the
preclinical stage and significant further work is required to
determine the associated risks of tumor formation, immune
reactions and graft-induced dyskinesias before clinical
trials can be implemented [24]. Moreover, some of the initial
enthusiasm for cell transplantation as a potential cure has
dissipated following reports that alpha-synuclein pathology
may re-emerge in transplanted cells [15]. For these various
reasons, there is now increasing interest in symptomatic
treatment through the re-engineering of healthy non-dopa-
minergic cells either to produce neuroprotective growth fac-
tors, to rebalance pathological networks or even to generate
dopamine. This is the growing field of pharmacogenetics,
which has resulted in a number of new agents progressing
to human trials.
Pharmacogenetics involves the delivery of selected genes
to specific targets in the brain with the aim of reprogramming
the function of healthy cells to strengthen or take over from
the susceptible cell population, here, dopaminergic neurons.
Peripheral administration is limited by the impervious nature
of the blood–brain barrier to many of the vectors and agents
that have therapeutic potential, and thus primary delivery is
usually achieved by stereotactic injection, harnessing tech-
niques from the world of DBS. In order to integrate the
genes into the host neuron a vector is required and this can
take non-viral or viral forms [25]. Non-viral methods, such
as polyplex synthetic nanocarriers and immunoliposomes,
haveshownsomesuccess in animalmodelsbut demonstrate
limited and transient expression of transduced material and
are therefore at an early pre-clinical stage of testing [26–28].
In order to achieve continuous, long-lasting gene expression,
viral vectors, with their ability to integrate genetic material
into thepatient’sgenomeorconstruct intracellular episomes,
currently appear most encouraging. A number of different
families of viruses have shown promise for pharmacogenetic
manipulation. The most favorable and clinically developed
advances relate to adeno-associated virus (AAV) vectors
and lentivirus vectors. AAVs are relatively small single-
stranded DNA viruses of the Parvoviridae family that have a
genome of around 4.7 kilobases. AAVs have been shown to
lead to persistent functional integration over aperiod of years
and, for PD, they have the advantage that they can demon-
strate a degree of specificity for neurons of the basal ganglia[29–32]. Their small size, however, limits their genetic delivery
capacity to a single neurotrophin or enzyme. Ideally, a vector
should have the capacity to insert multiple genetic units that
could act synergistically to enhance therapeutic efficacy. A
larger,more accommodating, class of viruses is the lentivirus
family, which is a group of retroviruses with a genome typi-
cally of about 10 kilobases. Initial concerns regarding po-
tential oncogenicity due to chromosomal integration have
partially been addressed through the creation of non-inte-
grating lentiviruses that can be directed to drive expression
transiently in dividing cells or in a sustained manner in non-
dividing cells [33]. Both AAVs and lentiviruses have now
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pharmacogenetic approaches, including neuroprotective
growth factor transduction, physiological network rebalanc-
ing through upregulation of gamma-aminobutyric acid
(GABA) and reprogramming of non-dopaminergic neural
tissue to produce dopamine.
Pharmacogenetic Neuroprotection
Neurotrophins are a collection of molecules that act on neu-
rons to regulate and promote cell growth and survival and
have shown promise in slowing dopaminergic denervation
in PD. Glial-cell-derived neurotrophic factor (GDNF) directly
injected into the striatum of parkinsonian mice demon-
strated both neuroprotective effects and positive motor out-
comes, but was subsequently not found to be efficacious in
human trials [34,35]. Presuming inadequate neurotrophin
penetration in early studies, pharmacogenetic approaches
using both lentivirus and AAV vectors have since been em-
ployed which could lead to more widespread and long-
term transduction of neurotrophins. Initial success with
an AAV2–GDNF vector in monkeys rendered parkinsonian
by the systemic application of the neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) has led to open-
label, and hence unblinded, phase I clinical trials, expected
to be completed in 2018 [36,37]. Neurturin has functional
similarities to GDNF and has also shown efficacy when deliv-
ered through an AAV vector in pre-clinical studies, although
these have not yet translated into motor improvements or
disease modification in robust double-blinded clinical trials
[38,39]. A repeat study of AAV–Neurturin with higher dosages
and longer follow-up times is currently underway.
Pharmacogenetic Network Compensation
Classically, dopamine depletion within the basal ganglia is
believed to lead to underactivity of the direct pathway, which
favours movement and bypasses the STN, and overactivity
of the indirect pathway, which suppresses movement and
involves the STN (Figure 1) [40]. An alternative approach to
replacing dopamine then would be to rebalance the two
pathways by inhibition of the subthalamic nucleus and indi-
rect pathways, a policy supported by the partial success of
lesional surgery andDBS of this target [41,42]. This rebalanc-
ing could potentially be achieved pharmacogenetically by
enhancing local GABA concentrations within the subthala-
mic nucleus. Glutamic acid decarboxylase (GAD) catalyses
the rate-limiting step of GABA formation and has therefore
been the focus for this form of pharmacogenetic manipula-
tion. AAV–GAD treatment of parkinsonian rats demonstrated
increased GABA release in the subthalamic nucleus and an
improvement in motor output [43]. Following this, an open-
label phase I study of patients using unilateral AAV–GAD
injection to the subthalamic nucleus was performed and
revealed a reduction of ipsilateral thalamic metabolism
and improved contralateral motor scores at three and
twelve months [44]. A follow-up double-blind randomised
study confirmed both the safety and efficacy of bilateral
AAV–GAD delivery to the same nucleus, but motor benefit
was modest and rather less than that achievable with con-
ventional DBS [45].
Pharmacogenetic Dopaminergic Replacement
It has long been argued that intermittent, pulsatile dopami-
nergic therapy leads to plastic changes in the motor system
that may be responsible for the late emergence of motorfluctuations and dyskinesias [46]. Given that the biochemical
pathways that convert L-tyrosine to levodopa are well
described, could pharmacogenetics be used to augment
endogenous dopamine production through repurposing
existing healthy non-dopaminergic neurons? A number of
approaches involving all steps of the dopaminergic pathway
have been attempted. Aromatic amino acid decarboxylase
(AADC) converts levodopa to dopamine; therefore, as dopa-
minergic neurons containing AADC degenerate in PD, total
levels of the enzyme are reduced and the efficacy of levo-
dopa drops. AADC substitution could then both improve
motor symptoms and reduce the total exogenous levodopa
requirements, reducing side effects. Such long-lasting ef-
fects have been shown inMPTP-treatedmonkeys [47]. In hu-
man studies, however, the clinical improvement has so far
only been short lived, even though there was evidence that
the genetic and biochemical effects were permanent [47,48].
A more advanced and potentially efficacious approach
might therefore be to transfect a genetic package containing
genes for the complete dopamine synthesis pathway,
including AADC but also tyrosine hydroxylase, which con-
verts L-tyrosine to levodopa, and guanosine triphosphate
(GTP)-cyclohydrolase-1, which facilitates this conversion
by synthesising tetrahydrobiopterin, a cofactor for tyrosine
hydroxylase (Figure 2). This represents the most ambitious
pharmacogenetic therapy to date, attempting to transduce
the entire dopaminergic synthetic pathway into non-dopami-
nergic neurons of the striatum. For this, a lentivirus was
loaded with genes for all three enzymes in the dopamine
pathway and the complete package named ProSavin. Pre-
clinical studies in MPTP-treated monkeys demonstrated
that ProSavin increased extracellular dopamine levels and
improved motor function, which was sustained at one year
[49]. Recent results from a preliminary study in humans
are also encouraging. In this open-label study, 15 patients
were treated with stereotactic striatal injections of ProSavin
at three different doses [50]. There was a modest-to-moder-
ate improvement in motor performance with the suggestion
of a dose-response effect that was sustained at 12 months.
This was accompanied by evidence of a sustained increase
in endogenous dopamine as revealed through decreased
binding of a competitive radionucleotide (11C-raclopride)
during positron emission tomography (PET) imaging
(Figure 2). Increased levels of dyskinesias were experienced,
in keeping with the therapeutic mechanism of ProSavin, and
were managed with drug adjustment. Double-blind rando-
mised studies are needed to determine whether this treat-
ment gives clinically meaningful improvements in motor
function and how this compares to conventional treatment
with medication and DBS.
One outstanding question related to cell transplantation
and pharmacogenetic techniques is the extent to which
they may be eventually expected to lead to circuit-specific,
temporally defined synaptic interactions with selected, func-
tionally appropriate targets. Still, they may suffice in
providing an essential tonic dopaminergic input necessary
to maintain physiological function within a circuit which,
although dynamic, is predicated on a particular balance of
inputs. This is, after all, how pharmacological therapies like
levodopa work, and these newer approaches would have
the additional advantage of avoiding the coarse fluctuation
in dopaminergic input that is implicated in the genesis of
dyskinesias and unpredictable motor states experienced in
more advanced cases of PD.
Figure 2. Schematic of pharmacogenetic
replacement of complete dopamine synthesis
pathway and radionucleotide evidence of
increased endogenous dopamine production
following treatment.
(A) Dopamine (DA) synthesis pathway in
healthy brain. The rate-limiting enzyme for
DA synthesis in normal brain is tyrosine hy-
droxylase (TH), which requires tetrahydro-
biopterin (BH4) as cofactor. BH4 synthesis is
dependent on GTP cyclohydrolase (GTPCH).
Dihydroxyphenylalanine (DOPA) produced
by TH is converted to DA by L-aromatic amino
acid decarboxylase (L-AAADC), which in the
normal brain is packaged into synaptic vesi-
cles by vesicular monoamine transporter
type 2 (VMAT2). In the normal brain, the effect
of DA released into the synapse is terminated
by reuptake through DA transporter (DAT) and
synthesis and release are regulated by D2-like
autoreceptors (D2 AR). (B) Gene therapy using
ProSavin causes striatal neurons to express
TH, GTPCH, and L-AAADC, and thereby en-
ables them to produce DA. (C) Two-dimen-
sional fluid attenuated inversion recovery
MRI sequences from 1 month after bilateral
surgery (left), showing increased signal within
the postcommissural (PostCom) putamen
corresponding to motor putamen injection
sites (lower arrow), and no signal change in
the non-injected caudate nucleus (upper ar-
row). Binding potential parametric maps
from 11C-raclopride PET scans of a single pa-
tient carried out at baseline (middle) and
6months after bilateral ProSavin injection (right) within the putamen. Hot colours demonstrate increased raclopride binding and hence diminished
endogenous dopamine. Note a decrease in the binding potential index only in the left and right postcommissural putamen area (middle, lower
arrow), compared with no binding potential change on either side of the non-injected caudate nucleus (middle, upper arrow), indicating increased
endogenous dopamine at sites of ProSavin injections. Adapted with permission [50,103].
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A very different approach is to ameliorate the dysfunctional
circuit dynamics that result from dopaminergic denervation.
But what are these abnormal circuit dynamics? Early con-
ceptualisations of basal ganglia function invoked an imbal-
ance between two opposing streams: the direct and the
indirect pathways [40] (Figure 1). This relatively simple
model, which was predicated on a pure rate coding scheme,
was remarkably successful in explaining numerous experi-
mental results relating to the basal ganglia, in addition to a
number of clinical disorders such as PD. However, objec-
tions to a model based simply on average neuronal firing
rates have subsequently come from anatomical, physiolog-
ical and clinical studies, including the paradoxically benefi-
cial effect of DBS on the globus pallidus interna [51–53].
Indeed, basal ganglia recordings from non-human primates
demonstrating oscillatory single-unit and population activity
in the dopamine-deficient state have since been corrobo-
rated by studies in patients with PD that show bursts of
similar activity, albeit at slightly higher frequencies, in the
beta range (12–35 Hz) [54]. This signature marker of PD
poses a challenge to simple rate-based coding accounts
of basal ganglia function, with the emergence of bursts
of synchronised activity in the dopamine-deficient state
demonstrating that dopamine controls patterns of neuronal
activation in addition to simply modulating the rate of firing.
Synchronisation of activity in the beta band is widely distrib-
uted with cortical, subcortical and cortico-subcortical con-
nectivity [55–57]. Beta activity in the cortex temporallyprecedes that in the basal ganglia and reduced dopami-
nergic function strengthens effective connectivity in the
hyperdirect pathway from cortex to the subthalamic nucleus
[58]. Reciprocal connections between the subthalamic nu-
cleus and globus pallidus externa are also dopaminergic
dependent, amplifying subcortical oscillations when dopa-
mine is low [59]. The subthalamic nucleus thus emerges
as a key node through which to interact with this circuit
dysfunction.
Nevertheless, it remains unclear how DBS of the subthala-
mic nucleus — the most popular target for the surgical treat-
ment of PD — works. Due to anatomical correspondence
between DBS and earlier lesional targeting, the mechanism
was initially presumed to represent a functional lesion [60].
Although there is some evidence of local somal inhibition,
there is also now strong support for both antidromic and
orthodromic axonal activation [61]. This suggests that local
delivery of DBS pulses leads to a widely distributed modula-
tion of the motor network. In particular, stimulation serves
to suppress pathologically synchronised oscillations in a
similar manner to levodopa administration [62,63].
Although clinically effective, DBS is still limited by costs,
side effects and partial efficacy. Current clinical stimulation
is open-loop with fixed stimulation settings leading to relent-
less interference in motor networks. This inevitably causes
disruption of physiological, in addition to pathological, pro-
cessing. Consequently, DBS may cause motor, speech
and executive side effects [64–67]. Might it be possible to
limit stimulation to times when circuit disturbance is more
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ing? The upshot would be reduced side effects and power
consumption but also, potentially, improved efficacy, if the
benefits of suppressing pathological activity in themotor cir-
cuit with conventional DBSwere partly offset simultaneously
by effects on residual physiological motor processing. Trig-
gering the delivery of DBS by increases in the very patholog-
ical activity that it suppresses would offer a simple solution,
much more tractable than following the patient’s clinical
state with multiple limb-mounted sensors or motion detec-
tion systems in the environment. This adaptive approach
to brain stimulation has recently been successfully applied
in the treatment of epilepsy [68]. However, pathological ac-
tivity in epilepsy is paroxysmal and discrete, so how might
on-demand stimulation fare in disorders with more persis-
tent dysfunction? Fortunately, there is mounting evidence
in non-human primate models and patients with PD that
this form of adaptive DBS can provemore efficacious formo-
tor control than standard continuous high-frequency DBS,
despite reductions in overall stimulation. Furthermore, the
opportunity afforded by DBS in patients allows for the inves-
tigation of neural network activity within the basal ganglia
through the recording of single-cell and local field potential
activity in awake human subjects, furthering our understand-
ing of motor and cognitive systems.
Rosin et al. [69] elegantly demonstrated effective adaptive
stimulation in a non-human primate model of PD. They
tested two MPTP-treated parkinsonian monkeys. Surgical
implantation of microelectrodes in the motor cortex and
the globus pallidus interna of the monkeys enabled
recording from individual neurons at the two sites during
stimulation of the globus pallidus interna. The aim of this
study was to assess whether delivering stimulation accord-
ing to the pattern of firing of neurons was able to improve
parkinsonism over and above that of standard continuous
(open-loop) high-frequency stimulation. In addition, they
set out to determine whether pattern-triggered stimulation
had dissociable effects on cortico-basal ganglia oscilla-
tions and neuronal firing discharge rates. A number of
different closed-loop paradigms were examined with the
most effective resulting from triggering from the firing of
motor cortical neurons and stimulation in the globus pallidus
internawith short trains of seven pulses at 130Hz at a latency
of 80 milliseconds (Figure 3). In the MPTP model, the domi-
nant circuit oscillation that results is 12.5 Hz and thus an
80 millisecond delay corresponds to stimulating at the start
of the next oscillatory cycle. Neuronal activity was recorded
in the globus pallidus interna before, during and after stimu-
lation. The clinical effect of stimulation was a marked reduc-
tion in bradykinesia, which was most pronounced in the
limb contralateral to stimulation. Notably, the improvement
was substantially greater than that achieved with standard
high-frequency stimulation despite the significantly lower
overall charge delivery. These compelling behavioral im-
provements were accompanied by a reduction in pallidal
discharge rate and oscillatory activity which was more pro-
nounced with adaptive stimulation compared with the stan-
dard high-frequency condition, despite the lower overall
number of stimuli. Furthermore, they found that if the para-
digm were changed so that sensing and stimulating both
occurred in the globus pallidus interna, bradykinesia was
worsened. Importantly, this occurred in the context of firing
rates that were still reduced but with increased oscillatory
bursting. Further, the authors found no correlation betweenpallidal firing rate and oscillatory activity, suggesting inde-
pendent mechanisms. As such, it appears that bradykinesia
relates more strongly to oscillatory activity, not firing rate,
affording critical support for the concept that low-frequency
oscillations play a key pathophysiological role in PD. Addi-
tionally, this seminal experiment provided proof of concept
that adaptive DBS can be efficacious and, most notably,
can actually be more effective than conventional DBS,
despite a reduction in overall stimulation.
This research in MPTP-treated non-human primates has
now been complemented by work in patients with PD;
here, the strategy has, however, been subtly different. The
study described above used the firing of motor cortical neu-
rons to trigger stimulation in the globus pallidus interna.
However, recordings from individual neurons are difficult
to sustain over prolonged periods and require additional sur-
gical instrumentation, so are not an ideal feedback signal for
adaptive DBS in patients requiring stimulation over many
years [70]. An alternative approach is to use a feedback
signal recorded directly from the stimulating electrode. Local
field potentials principally represent the summation of syn-
aptic currents in the population of neurons local to the elec-
trode [71]. These signals remain robust over many years of
recording and potentially contain greater informational con-
tent than single neurons [70,72]. Beta oscillations can be re-
corded in local field potentials from the subthalamic nucleus
in the vast majority of patients with PD withdrawn from oral
medication and are suppressed by levodopa andDBS in pro-
portion to clinical improvement [63,73,74]. The parallel mod-
ulation of beta activity with motor function suggests that
beta activity could be used to track clinical state and act as
feedback to trigger adaptive DBS. This hypothesis has
recently been tested in patients [75]. Here, beta oscillations
were amplified and filtered around the patient-specific beta
peak and an on-line (i.e. real time) measure of amplitude
derived (Figure 4). A threshold was then set which resulted
in a trigger signal being sent to a stimulator when beta ampli-
tude crossed above the trigger threshold. Triggering of the
stimulator switched on the conventional high-frequency
stimulation. The stimulation voltage was ramped up so as
to avoid the discomfort sometimes experienced with abrupt
stimulation onset. What was surprising about this study was
that, despite a 50% reduction in overall stimulation, motor
function was 30% better than with conventional continuous
stimulation. Supporting the critical role of beta oscillations
in PD, beta activity was also suppressed in proportion to clin-
ical improvement across conditions.
The above study also revealed an unexpected result; there
was a progressive reduction in total time on stimulation
despite a fixed trigger threshold, pointing to a gradual dimi-
nution of the frequency of beta bursts during adaptive
stimulation (Figure 4). This suggests that more temporally
focused stimulation might encourage beneficial plasticity
in the motor circuit. Overall, the study demonstrated that
even using a simple control system with a single feedback
signal, significant gains can be made in terms of power con-
sumption and motor improvement. Moreover, this simple
but tractable system could soon be realised in chronically
internalised patients using new devices with the capability to
simultaneously sense and stimulate [76]. Further studies are
now necessary to establish the long-term viability of adap-
tive DBS and to establish that side effects are diminished
relative to standard treatment, in line with the lower power
demands of the former. Other work aimed at optimisation
Figure 3. Closed-loop DBS in the non-human primate with physiological and behavioral results.
(A–C) Examples of 7 second traces of spiking activity in a GPi neuron before (A), during (B), and after (C) closed-loop stimulation of globus pallidus
with a brief train of electrical shocks triggered by neuronal spikes in the motor cortex after a delay of 80 milliseconds. The stimulus artifact is
shown in red (B, left box), as is the residual artifact after artifact template removal (B, right box). (D) Oscillatory activity depicted through wavelet
spectrograms and displayed by frequency as a function of time, with blue to red color indicating the intensity of activity. Spectrograms of activity
before (left column), during (middle column), and after (right column) the application of closed-loop stimulation are shown. Estimates of oscillatory
activity averaged over time are shown to the right of each panel, and are relative to the maximal oscillatory power in the entire recording from this
neuron. (E) 100 second trace of themotion signal from an accelerometer fastened to the primate’s limb contralateral to the stimulating electrodes.
Trace starts 50 seconds before the onset of stimulation. Stimulus raster is depicted in red in the upper trace. Movement increases dramatically
once stimulation starts. (F) Characteristics of the triggered stimulus pattern. Triggered stimulation consisted of a train of seven pulses of stimu-
lation at 130 Hz (expanded bottom raster). Triggering was episodic (top raster). Adapted with permission [69].
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before adaptive DBS can realise its full potential. Moreover,
evidence is now accumulating that variations in beta band
activity alone do not capture all aspects of PD and that
beta activity may interact with other signals, such as gamma
activity, through excessive phase-amplitude coupling at
both cortical and sub-cortical levels [77,78]. It remains to
be seen whether more sophisticated spectral biomarkers
may capture greater degrees of PD phenomenology and
may therefore prove useful in adaptive DBS. However, any
potential advantages of such biomarkers may be offset by
their higher complexity, which may increase the power con-
sumption necessary for on-line detection and analysis and
slow the response of the DBS system to changes in physio-
logical state.
The above form of adaptive DBS relies on the feedback
signal, i.e. beta activity in the local field potential, being a
faithful correlate of clinical state from moment to moment.Obviously, this link between feedback signal and clinical
state will be tighter if pathological beta activity is mechanis-
tically involved in motor impairment, but this is not a prereq-
uisite. Yet, if beta activity were causally involved in motor
symptomatology, then stimulation patterns could potentially
be chosen that specifically target this rhythm in the hope that
these would be more efficacious, and again more selective,
than standard high-frequency stimulation. There is certainly
some evidence that beta oscillations may bemechanistically
important with studies showing that stimulating motor sites
within the beta range causes a slowing of movement and
an increase in rigidity, but the scale of such deleterious ef-
fects is limited [79,80]. Accordingly, it is as yet still not certain
whether pathological beta activity is quantitatively important
in the generation of bradykinesia and rigidity.
For this reason, attempts to specifically target mechanisti-
cally relevant oscillatory activity have focused on tremor in
PD. Parkinsonian tremor usually occurs at rest and is likely
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Figure 4. Adaptive, closed-loop stimulation in humans with PD using a local field potential (LFP) feedback.
(A) Left, schematic demonstrating DBS electrode in situwith simultaneous recording and stimulation. Right, example data demonstrating bipolar
LFPs recorded from the blue contacts at the end of the electrode. LFP is shown after wide band (3–37 Hz) filtering (bottom trace) and following
narrow band filtering around the patient-specific beta peak (second trace). Rectification and smoothing produced a beta amplitude signal (third
trace) with trigger threshold shown overlaid (horizontal blue line). Threshold crossing by beta amplitude resulted in a trigger signal to the stimu-
lator (fourth trace) and ramped high frequency stimulation delivered to patient (top trace). (B) Clinical motor improvement comparing conventional
(cDBS), adaptive (aDBS) and random stimulation. Note adaptive DBS is significantly superior to both conventional DBS and random stimulation.
(C) Example from one subject demonstrating progressive reduction in percentage time that stimulation is triggered per 10 second block (y-axis)
as time elapses (x-axis) despite a constant beta threshold. Thus, beta activity must have been falling over time, leading to less triggering per
10 second block. This suggests short-term plasticity. Adapted with permission [75].
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R904to have a different pathophysiological basis to bradykinesia
and rigidity [81]. In particular, it is locked to oscillatory activ-
ity in the cortico-basal ganglia loop at tremor and double
tremor frequency [82]. Tremor-related activity in the motor
cortex is likely to be intimately related to the generation of
tremor because extirpation of the motor cortex or sectioning
of the pathways leading from it have been shown to abolish
parkinsonian tremor [83]. Attempts to directly interfere with
these pathological oscillations have taken two general
forms. The first leverages an old technique called active
noise cancellation. In order to improve communication with
pilots in noisy cockpits, engineers in the 1950s devised a
system in which ambient surrounding noise was recorded,
inverted and played back to pilots through headphones
in real time. Noise-cancelling headphones thus resulted
in cancellation of unwanted sounds and a higher signal-to-
noise ratio in the audio domain. A similar approach was
recently adopted to cancel cortical oscillations within
the tremor network in PD [84]. PD patients were fitted
with an accelerometer to measure tremor and non-invasivetranscranial alternating current stimulation (tACS) delivered
through a sponge pad placed over the scalp overlying the
motor cortex (Figure 5). The frequency of tACS was chosen
to be very close to that of the intrinsic tremor frequency.
This resulted in a gradual drifting of the two oscillations in
and out of phase with each other every three or so seconds
and enabled an off-line analysis of the effect on tremor ampli-
tude of the phase difference between stimulation and tremor.
The technique identified phase regions in which tremor was
amplified and suppressed (i.e. in line with cancellation), but
sizes of the effect were modest, in the range of 10%. Never-
theless, the authors went on to track tremor phase so that
they could actively keep the phase difference between the
stimulation and tremor at an optimal level for tremor sup-
pression. The effect of stimulationwas thenmuchmore strik-
ing, with an average 50% reduction in tremor amplitude
even though stimulation duration was limited to 30 seconds.
This approach is now being tested with even longer periods
of stimulation. Ultimately, in order to be tractable over years,
as is necessary for a clinical intervention, this kind of
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Figure 5. Adaptive transcranial alternating
current stimulation (tACS) aiming to cancel
oscillatory activity.
(A) Schematic demonstrating recording of
tremor signal via accelerometer (blue) and de-
livery of phase-shifted tACS signal at the same
frequency (red). Phase cancellation occurs
when the two signals are out of phase and
added together (black). (B) Percentage change
in tremor amplitude with shifting phase align-
ment between tremor and stimulation in one
subject during 30 seconds of phase tracking
in blocks with optimal phase position for sup-
pression shown with red arrow. Note certain
phases enhance tremor whereas opposing
phases suppress tremor. (C) Example of tremor
(top trace) and tACS (bottom trace) delivered at
the optimal phase for suppression in one
patient. Note that the tremor is completely sup-
pressed by tACS around 30 seconds in to the
recording time, suggesting a cumulative effect
of stimulation. Adapted with permission [84].
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R905stimulation would be delivered through subgaleal or extra-
dural electrodes, although this is still considerably safer
than DBS, which involves penetrating the brain substance.
The phase cancellation of pathological oscillations by
tACS is ideally suited to structures that are essentially planar,
like the cerebral cortex, so that flat stimulating electrodes
maintain a more-or-less fixed distance from the relevant
laminar elements. However, this is not possible in nuclear
structures where neurons are more intermixed so that these
may be subject to phase cancellation at one depth but not at
others due to field gradients. Indeed, neurons may actually
end up driven by the stimulation at levels more proximal
to the stimulation source. For such structures it may be
more appropriate to attenuate pathological oscillatory activ-
ity with pulsatile electrical stimuli that shift oscillators out
of their preferred regimes with an all-or-nothing effect. This
likely involves two processes. Stimuli delivered at certain
phases of a pathological oscillatory activity will phase
advance or phase delay neuronal responses in their oscilla-
tory cycle [85,86]. Provided that stimulation is not supramax-
imal the net result is to partially desynchronise the oscillatory
network, and to reduce its peripheral manifestation in the
form of tremor. However, cumulative effects may also be
expected as a result of short-term, spike-timing-dependent
plasticity. Both instantaneous and cumulative effects of
phase-locked pulsed stimulation have recently been demon-
strated in patients with essential tremor in whom the thal-
amus was directly stimulated as a treatment for tremor
[87]. In addition, cumulative effects were suggested during
phase-cancelling tACS for tremor (Figure 5C) [84].
The above approach can potentially be optimised still
further by leveraging the multiple contacts of DBS elec-
trodes. Here, pulsed stimulation is differentially patterned
over the electrode contacts to fragment a previously syn-
chronised neuronal population into a cluster of subpopula-
tions, the phases of which are shifted with respect to each
other [88]. These clusters may then desynchronise further
before finally resynchronising unless re-stimulated. The
timing of further stimulation can be feedback controlled or
pre-determined. The technique, termed coordinated reset,
was first developed to treat tremor [88], although more
recently it has been piloted for the lower beta band
oscillations in the subthalamic nucleus of MPTP-treatedmonkeys, where it has surprisingly long-lasting effects on
movement [89].
These different approaches to more tailored therapeutic
brain stimulation are linked by their exploitation of the fluctu-
ation of pathological neuronal activity over time; either
the fluctuation inherent within cycles of oscillatory activity
or the slower fluctuations in the amplitude of the envelope
of such activity. This tailoring to temporal characteristics
affords the interventions a degree of specificity as intact
physiological activities are not yoked in time to patholo-
gical activity. Spatial specificity is, however, still limited.
Yet moves are afoot to improve the resolution of electrical in-
terfaces with the brain. Current clinical DBS electrode tech-
nology, for instance, employs a quadripolar electrode with
four circular contacts of 1.5 mm length. Recent work has
introduced a newdirectional electrodewhich has been found
intra-operatively to improve the therapeutic window of
stimulation [90]. Importantly, if this translates into a clinically
realisable therapy, this could also be combined with the
temporal techniques described above to provide combined
spatiotemporally targeted DBS. However, the new field of
optogenetics promises a means of combining temporal
specificity with the ultimate in spatial specificity — the stim-
ulation of neurons of a specific cell type within a controlled
region.
Optogenetics
Opsins are light-sensitive receptors that are naturally pre-
sent in humans in the form of rod opsins (rhodopsin) and
cone opsins (photopsin) in the eye. Reactivity to light con-
verts photic energy into a neuroelectrical signal for down-
stream visual processing. Similar proteins exist within the
prokaryotic world (type I opsins) and these have recently
been leveraged for in vivo experimentation on mammals.
In 2005, Deisseroth and colleagues [91] demonstrated the
functional integration of light-sensitive channelrhodopsin-2
(ChR2) into mammalian neurons using a lentivirus gene
vector. ChR2 is a light-gated cation channel that has very
rapid temporal kinetics and is sensitive to blue light in the
450–490 nm range. Illumination with an appropriate light
source led to abrupt depolarisation with a latency of only
2 milliseconds, sufficient to cause firing of the neuron. These
authors were then able to show entrainment of spiking
BA
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Figure 6. Selective optical control of afferent
fibers in the STN using optogenetics in a
6-OHDAmousemodel of Parkinson’s disease.
(A) Optical high-frequency stimulation (HFS)
at 130 Hz to afferent fibers in the STN region
of an anesthetized mouse with 473 nm light-
inhibited STN spikes (top left). Optical low-fre-
quency stimulation (LFS) at 20 Hz produced
reliable spiking at 20Hz (bottom left). Top right
panel shows that HFS still allowed very low
frequency activity in the STN. Bottom right
panel confirms that LFS did drive 20 Hz activ-
ity in the STN, but again left very low frequency
activity unchanged. The effect of optical stim-
ulation was therefore frequency selective, and
only seen during light exposure and not before
or after exposure. (B) Optical HFS to STN in
these animals produced robust therapeutic
effects, reducing apomorphine-induced ipsi-
lateral rotations (a measure of parkinsonism
in this model). In contrast, optical LFS exacer-
bated pathological effects, causing increased
ipsilateral rotations. Both effects were revers-
ible and highly statistically significant. The
two panels to the left demonstrate effects of
different forms of stimulation within animals.
The right-hand panel summarises group-level
effects as percentage change in rotations per
minute. An increase in rotations represents
a worsening of the parkinsonian deficit.
Adapted from [92]: reprinted with permission
from AAAS.
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R906neurons with their extrinsically delivered light pulses. As
such, this demonstrated the potential for high-fidelity tempo-
ral control of individual neuronal spikes using only a light
source. These initial exciting results have been followed up
by a wealth of powerful studies that have sought tomodulate
circuits in freely behaving animals to further elucidate the
pathophysiological role of specific brain structures and
indeed specific types of neurons.
Models of PD were among the first to benefit from such an
approach. Here the same group used both ChR2 and a dif-
ferent class of opsins, namely the halorhodopsins (NpHR),
involving a light-activated chloride pump that hyperpolarises
neurons and inhibits firing of action potentials to differentially
control selected cell groups within and around the basal
ganglia [92]. First they tested whether direct inhibition of
the subthalamic nucleus would have therapeutic potential
in a rodent model of PD using NpHR inhibitory modulation.
This was physiologically effective, leading to an 80% reduc-
tion in spiking in neurons in the subthalamic nucleus. How-
ever, whereas electrical stimulation with DBS at the same
site led to a marked and significant reduction in pathological
rotational activity (their behavioral marker of parkinsonism),
NpHR-mediated inhibition of the subthalamic nucleus had
no effect on motor output. Instead, they demonstrated thathigh-frequency optogenetic stimula-
tionof afferent fibres leading to thesub-
thalamic nucleus both greatly reduced
spiking within the nucleus and led to a
robust improvement in pathological
rotation (Figure 6). Further testing re-
vealed that similar motor improvement
could also be achieved by optical stim-
ulation of layer 5 projection neurons inthe motor cortex, suggesting that the white matter connec-
tion between the cortex and subthalamic nucleus, termed
the hyperdirect pathway, was critical in mediating the effects
of stimulation. Moreover, the effect of stimulation of afferent
fibres to the nucleus was frequency specific; optogenetic
stimulation at 20 Hz worsened pathological motor activity,
consistent with the purported role of exaggerated beta
band oscillations in parkinsonian motor impairment.
A follow-up study was able to go further and dissect the
functional roles of the direct and indirect pathways of the
basal ganglia by optical stimulation of virally transduced
ChR2 receptors that were under the differential control
of regulatory elements for the dopamine D1 or D2 sub-
types (Figure 1) [93]. Excitation of the D2-expressing indi-
rect pathway induced parkinsonian symptoms, including
freezing and bradykinesia, whereas activation of the D1-ex-
pressing direct pathway ameliorated the same symptoms
in parkinsonian rodents. This provides some support for
the classic model of basal ganglia function [40] and, taken
together with earlier studies, suggests that both rate and
pattern coding coexist within the basal ganglia, at least in
the context of disease. Optogenetic techniques have since
been used to explore many features of striatal function and
have proven a boon in linking cell-type-specific function to
Special Issue
R907behavioral change in animal models of neuropsychiatric dis-
orders [94,95]. More recent advances have linked opsins not
just to ion channels but to a range of intracellular signaling
pathways via new G-protein-coupled receptors termed
OptoXRs [96]. This allows for the manipulation of the excit-
ability of target populations of neurons without specifically
controlling spike timing. Furthermore, flexible optical control
of gene transcription has also been achieved, which opens
up an ever greater range of possible experimental and poten-
tially therapeutic interventions [97]. Theoretically then, opto-
genetics holds considerable promise for correcting network
level dysfunction in patients with PD and other neuropsychi-
atric diseases [98].
Although it is clear that optogenetics can play a valuable
role in dissecting pathophysiology through discriminative
circuit-level control and can specifically ameliorate motor
deficits in rodent models of PD, there are a number of
technical, practical and regulatory challenges to overcome
before this can be translated clinically [99]. Expression of op-
sins using viral vectors still remains to be proven safe and
effective in humans. Additionally, optogenetics is currently
vastly more energy inefficient than electrical stimulation
techniques and this would, using current technology, greatly
limit device longevity and risk unacceptable tissue heating.
This could be circumvented by designing opsins with greater
light sensitivity and downstream signaling pathway amplifi-
cation or by engineering solutions [100,101]. Enthusiasm
for the therapeutic potential of optogenetics should also be
tempered by acknowledgement that the sophisticated level
of microcircuit control offered by this technique is not yet
fully supported by sufficient understanding of cell-type-spe-
cific contributions to aberrant chronocircuitry inmany neuro-
psychiatric diseases, including PD. These issues highlight
how clinical translation will require advances in multiple
different domains from basic physiology to bioengineering
and molecular technologies, and this confluence of technol-
ogies will make bridging the gap to patients especially chal-
lenging. Additionally, even if successfully translated, the
increased safety concerns mean that optogenetics would
then have to demonstrate superiority over established treat-
ments, such as medication and electrical interventions, and
this remains to be proven.
Conclusions
Neuroscientific advances are driving forward our under-
standing of neuropsychiatric disease and leading, in partic-
ular, to the development of novel treatments for PD.
Conceptualisations of disease pathology that are able to
include multi-scale formulations from genes to networks
are leading to new potential therapeutic approaches that
ambitiously attempt to re-engineer aberrant networks at all
levels. Pharmacogenetics aims to restore the local milieu
through expression of neuroprotective growth factors or
replacement of the dopaminergic synthesis pathway by
transduction into healthy cells. Adaptive DBS attempts to
modify distributed macro-networks using locally detected
neural signals to temporally direct stimulation to periods of
heightened pathological activity. Furthermore, population-
based signals such as local field potentials might not simply
be sources of feedback, but might actually reflect population
dynamics that are central to the pathophysiology. These
could then be direct targets for interventions by phase-
cancelling or -disruption techniques that use electricity to
interface with the brain. Finally, the micro- and macro-scalesare brought together in the field of optogenetics, which has
already afforded new insights into the pathophysiology of
PD and the mechanisms of its therapy. Translation to the
clinical environment for optogenetics and all emerging treat-
ments will require rigorous safety testing and robust trials
comparing them with existing clinical therapies. Neither
should we underestimate the challenges presented by PD,
for as yet the above advances are only targeted at those
mechanisms that relate tomotor impairment.We have barely
begun to consider interventions that might ameliorate other
disease features, such as the speech, gait and neuropsychi-
atric dysfunction that increasingly dominate in advanced
cases. There remains much to be done, but we have at least
entered into a phase of neuroscientific research that is
yielding important insights into pathophysiology and novel
therapeutic approaches.
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